The majority (62%) of first-in-class small-molecule drugs already come from phenotypic screens. It's not the future of pharma, it's the present.https://www.nature.com/articles/nrd3480 …
0 replies
0 retweets
2 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.